11/02/2026
I want to share an important update that could shape the future of menopause care in Australia.
In January, Australian pharmaceutical company Lawley Pharmaceuticals launched legal action after the PBAC declined to recommend PBS listing for AndroFeme 1, a female-specific testosterone treatment for post-menopausal women with distressing low libido (HSDD).
Here’s why this matters:
• Men have access to at least 8 PBS-subsidised testosterone products
• Women have access to none
• Women currently pay 14–16 times more for equivalent treatment
AndroFeme 1 has been TGA-registered since 2020 and is approved in Australia, the UK, NZ and South Africa, but remains privately funded here.
This isn’t just about one product. It’s about equity. It’s about whether women’s sexual health and quality of life are taken seriously.
I see the impact of this gap in care every day in my practice.
If this matters to you, please consider signing the Healthy Hormones petition calling for fair PBS access to testosterone for women.
Change in women’s health doesn’t happen quietly — it happens when we speak up together.
https://c.org/DgjvFXbM62